公开(公告)号：CA3122341A1

公开(公告)日：2020-06-18

申请号：CA3122341

申请日：2019-12-13

Applicant: UNIV HEALTH NETWORK

Inventor： KESHAVJEE SHAFIQUE ,  LIU MINGYAO ,  CYPEL MARCELO ,  SAGE ANDREW

IPC: G01N33/48 ,  G01N33/53 ,  G01N33/543 ,  G06F16/90 ,  G06N20/00

Abstract: Methods and kits for screening, diagnosing, detecting or predicting a patient outcome/risk variable for a lung transplant recipient after transplant or an EVLP outcome by measuring biomarker levels of at least three biomarkers selected from IL-6, IL-8, IL-10 and IL-1ß optionally in combination with one or both of sTNFR1 and sTREM1 in EVLP perfusate are described. The methods involve for example, i. obtaining one or more test EVLP perfusate samples of a donor lung; ii. determining in one or more test EVLP perfusate sample of a donor lung, a polypeptide level of the at least three biomarkers selected from IL-8, IL-6, IL-10 and IL-1ß and optionally one or both of sTNFR1 and sTREM1 i; and iii. a) comparing the one or more parameter values related to a level of the at least three biomarkers in the perfusate sample with control EVLP data or a cut-off level, wherein the differential level is indicative of outcome/risk of after transplant or of an EVLP outcome; or b) using the one or more parameter values related to a level of the at least three biomarkers in combination, as part of an algebraic calculation or model of outcome/risk.

公开(公告)号：CA3070522A1

公开(公告)日：2019-02-07

申请号：CA3070522

申请日：2018-07-30

Applicant: UNIV HEALTH NETWORK

Inventor： KESHAVJEE SHAFIQUE ,  LIU MINGYAO ,  CYPEL MARCELO ,  SAGE ANDREW

IPC: G01N33/48 ,  A61B5/00 ,  G01N33/53 ,  G01N33/543

Abstract: Methods and kits for screening, diagnosing, detecting or predicting a patient outcome/risk variable for a lung transplant recipient after transplant or an EVLP outcome by measuring biomarker levels of one or more biomarkers selected from IL-6, IL-8, sTNFR1 and sTREM-1 in EVLP perfusate are described. The methods involve for example, i. obtaining one or more test EVLP perfusate samples of a donor lung; ii. determining in one or more test EVLP perfusate sample of a donor lung, a polypeptide level of one or more biomarkers selected from IL-8, IL-6, sTNFR1 and sTREM-1; and iii. a) comparing the polypeptide level of the one or more biomarkers in the perfusate sample with a control or cut-off level, wherein the differential level is indicative of outcome/risk of after transplant or of an EVLP outcome; or b) using the polypeptide level of one or several of the one or more biomarkers in combination, as part of an algebraic calculation of outcome/risk.